// App-Quantinova.ai

: New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.

Researchers

Presenter

  • Gregory Russell Pond

Principal Investigators

  • Guenter Niegisch

  • Jonathan E. Rosenberg

  • Robert Dreicer

  • Thomas Powles

  • Andrea Necchi

  • Xiao X. Wei

  • Petros Grivas

  • Arjun Vasant Balar

  • Matt D. Galsky

  • Sandy Srinivas

  • Toni K. Choueiri

  • Joaquim Bellmunt

  • Dean F. Bajorin

  • Guru Sonpavde

Medical Centers

  • McMaster University, Hamilton, ON, Canada

  • Heinrich-Heine-Universitat, Dusseldorf, Germany

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of Virginia Emily Couric Clinical Cancer Center, Charlottesville, VA

  • Barts Health NHS Trust St Bartholomew's Hospital, London, United Kingdom

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Dana-Farber Cancer Institute, Boston, MA

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY

  • Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY

  • Dana-Farber-Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA

  • Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • N/A

Biomarkers

  • N-Acylethanolamine acid amidase

  • Neutrophil lymphocyte ratio

  • Programmed death-ligand 1

  • Human albumin

  • Lactate dehydrogenase

Drug/Treatment

  • Atezolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved